Document is current
Any future updates will be listed below
-
Authors
Ogata, Hiroaki
Tsubouchi, Kazuya
Takano, Tomotsugu
Ichiki, Katsuyuki
Torii, Ryo
Takata, Shohei
Nakagaki, Noriaki
Yoshida, Makoto
Kitasato, Yasuhiko
Tobino, Kazunori
Harada, Eiji
Wataya, Hiroshi
Ishii, Hiroshi
Maeyama, Takashige
Kawasaki, Masayuki
Fujita, Masaki
Yatera, Kazuhiro
Zaizen, Yoshiaki
Nakanishi, Yoichi
Okamoto, Isamu
-
Funding
Funding for this research was provided by:
the Clinical Research Promotion Foundation 2024 of Japan
the Ministry of Education, Culture, Sports, Science and Technology of Japan
the Broad-Area, Network-Based Project to Drive Clinical Research at Kyushu University Hospital
the Diffuse Lung Diseases Research Group from the Ministry of Health, Labor, and Welfare of Japan
- License Information
-
More Information
Article History
Received: 23 April 2025
Accepted: 30 May 2025
First Online: 30 May 2025
Declarations
:
: This prospective, multicenter observational study was approved by the Institutional Review Board of Kyushu University (#25–135, 23 August 2013; #555-00, 27 August 2013) and by the institutional review boards of all participating hospitals. Written informed consent was obtained from all participants. All study procedures were performed according to the ethical standards in the Declaration of Helsinki.
: K.Tsubouchi has received grants from Nippon Boehringer Ingelheim. S.T. has received personal fees from AstraZeneca, Boehringer Ingelheim Japan, Novartis Pharma, Sanofi, Bristol-Meyers Squibb, GlaxoSmithKline, Teijin Pharma, and Kyorin Pharmaceutical. K.Y. has received grants and personal fees from Chugai Pharmaceutical Co, Eli Lilly Japan K.K., TAIHO Phamaceutical Co., Ltd., Daiichi Sankyo Company, Limited., Shionogi & Co., Ltd., Insmed Incorporated., Nippon Boehringer Ingelheim Co. Ltd., Takeda Pharmaceutical Company Limited., and GlaxoSmithKline K.K.; grants from Sumitomo Pharma Co., Ltd., Kyowa Kirin Co., Ltd., FUJIFILM Toyama Chemical Co., Ltd., and TEIJIN HEALTHCARE LIMITED.; and personal fees from Sanofi K.K., KYORIN Pharmaceutical Co.,Ltd., Novartis Pharma K.K., Teijin Home Healthcare Limited., Asahi Kasei Pharma Corporation., AstraZeneca K.K., ONO PHARMACEUTICAL CO., LTD., MSD K.K, TOA EIYO LTD., and Meiji Seika Pharma Co., Ltd. Y.Z. has received personal fees from Nippon Boehringer Ingelheim Co. Ltd. I.O. has received grants and personal fees from Daiichi Sankyo, Chugai Pharma, Eli Lilly Japan, AstraZeneca, Taiho Pharmaceutical, Nippon Boehringer Ingelheim, and Ono Pharmaceutical; grants from Bristol-Myers Squibb and MSD Oncology; and personal fees from Takeda Pharmaceutical and Novartis Pharma. All other authors declare that they have no competing interests.
